无容量
易普利姆玛
医学
彭布罗利珠单抗
黑色素瘤
不利影响
免疫系统
脑炎
免疫检查点
免疫学
免疫疗法
抗体
肿瘤科
内科学
癌症研究
病毒
作者
Clara Martínez-Vila,Juan Carlos Laguna,Elia Seguí,G. Garrido Ruiz,Francisco Aya,Luis M. Fernandez-Morales,Julia Giner Joaquim,Joan Padrosa,Laia Fernández‐Barat,Lydia Gaba,Iván Victoria,Ana Arance
出处
期刊:Journal of Immunotherapy
[Ovid Technologies (Wolters Kluwer)]
日期:2021-05-05
卷期号:44 (5): 204-207
被引量:2
标识
DOI:10.1097/cji.0000000000000369
摘要
Since the approval of immune checkpoint anti–programmed cell death protein 1 antibodies (pembrolizumab and nivolumab) and anti–cytotoxic T-lymphocyte–associated protein 4 (ipilimumab) in combination or monotherapy, significant advances have been made in the treatment of metastatic melanoma. The nonspecific immune stimulation resulting from these drugs can case a wide range of side effects in many organs including the nervous system, named immune-related adverse events. Few immune-related encephalitis associated with these antibodies have been described in the literature. It is a rare complication (<1% of the total of immune-related adverse events) but it can be fatal if not diagnosed and treated on time. We describe 3 cases of patients with melanoma, which were treated with a combination of ipilimumab-nivolumab (case 1), ipilimumab monotherapy (case 2), and nivolumab monotherapy (case 3), who developed an encephalitis which was related to immune checkpoint therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI